Mafosfamide

Mafosfamide is a cytotoxic drug that belongs to the class of alkylating agents. It is a derivative of cyclophosphamide, a commonly used chemotherapy drug. Mafosfamide is designed to be activated in the body to produce a cytotoxic effect on cancer cells.

History

Mafosfamide was first synthesized in the 1980s as a potential anticancer agent. It was developed as a prodrug of 4-hydroxycyclophosphamide, the active metabolite of cyclophosphamide.

Mechanism of Action

Mafosfamide works by alkylating DNA, which prevents the DNA from being properly copied during cell division. This leads to cell death, particularly in rapidly dividing cells such as cancer cells. The drug is activated in the body by the enzyme cytochrome P450, which converts it into its active form.

Clinical Use

Mafosfamide has been studied in a variety of cancers, including leukemia, lymphoma, and solid tumors. However, it is not currently approved for use in any country.

Side Effects

Like other alkylating agents, mafosfamide can cause a number of side effects. These can include nausea, vomiting, hair loss, and bone marrow suppression.

Research

Research into mafosfamide is ongoing, with studies looking at its potential use in combination with other drugs, and in different types of cancer.

See Also

• Cyclophosphamide
• Alkylating antineoplastic agent
• Chemotherapy

‎

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian